Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular genetic tests in the prediction of the prognosis of breast cancer

Molecular genetic tests in the prediction of the prognosis of breast cancer Breast cancer is a heterogeneous disease concerning its morphology and behaviour. Until a few years ago, the prognosis of a given breast cancer case was mainly defined based on several parameters included in the pathology report: pTNM, grade, type, lymphovascular invasion, hormone receptor status and HER-2 status. The risk categories defined in the most recent St. Gallen consensus documents were complemented by the addition of the Ki67 index provisionally as a good marker for prognosis and for the risk of progressive disease. Newer assays are being developed to help augment these standard pathologic markers. The application of emerging molecular techniques in oncology is giving way to a variety of new prognostic and predictive tests designed to help tailor patient-specific treatment algorithms. While a few of these have accumulated sufficient validation to merit their use in the routine work-up of certain cancers, most still need additional studies to validate their roles in patient management. This review gives an overview of the major molecular pathology tests that are currently available for routine diagnostics. We provide information about their development, technical issues, and current and emerging utility as prognostic and/or predictive studies. Additionally, we discuss tests that are currently under investigation requiring additional validation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Molecular genetic tests in the prediction of the prognosis of breast cancer

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/molecular-genetic-tests-in-the-prediction-of-the-prognosis-of-breast-Ah0G1Uu99l
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0285-0
Publisher site
See Article on Publisher Site

Abstract

Breast cancer is a heterogeneous disease concerning its morphology and behaviour. Until a few years ago, the prognosis of a given breast cancer case was mainly defined based on several parameters included in the pathology report: pTNM, grade, type, lymphovascular invasion, hormone receptor status and HER-2 status. The risk categories defined in the most recent St. Gallen consensus documents were complemented by the addition of the Ki67 index provisionally as a good marker for prognosis and for the risk of progressive disease. Newer assays are being developed to help augment these standard pathologic markers. The application of emerging molecular techniques in oncology is giving way to a variety of new prognostic and predictive tests designed to help tailor patient-specific treatment algorithms. While a few of these have accumulated sufficient validation to merit their use in the routine work-up of certain cancers, most still need additional studies to validate their roles in patient management. This review gives an overview of the major molecular pathology tests that are currently available for routine diagnostics. We provide information about their development, technical issues, and current and emerging utility as prognostic and/or predictive studies. Additionally, we discuss tests that are currently under investigation requiring additional validation.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Oct 13, 2011

References

  • Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up
    Elston, CW; Ellis, IO
  • Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer
    Ravdin, PM
  • The Nottingham Prognostic Index in primary breast cancer
    Galea, MH
  • Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer
    Thorpe, SM
  • Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer
    McGuire, WL
  • Human breast cancer: correlation of relapse and survival with amplification of the ERBB2 oncogene
    Slamon, DJ
  • Studies of the ERBB2 proto-oncogene in human breast and ovarian cancer
    Slamon, DJ
  • Molecular portraits of human breast tumours
    Perou, CM
  • Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues
    Mullins, M
  • A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer
    Nielsen, TO
  • A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Paik, S
  • Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer
    Paik, S
  • Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Sotiriou, C
  • Genomic grade index is associated with response to chemotherapy in patients with breast cancer
    Liedtke, C
  • Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Wang, Y
  • Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature
    Tutt, A
  • Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer
    Konsti, J
  • Quantification of the proliferation index of human dermal fibroblast cultures with the ArrayScan high-content screening reader
    Gasparri, F
  • Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds
    Chang, HY
  • The prognostic role of a gene signature from tumorigenic breast-cancer cells
    Liu, R
  • Stromal gene expression predicts clinical outcome in breast cancer
    Finak, G
  • A focused, PCR based gene expression signature to refine grade in breast cancer
    Szasz, AM
  • Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
    Ayers, M
  • Increasing incidence of breast cancer in family with BRCA1 mutation
    Narod, S
  • Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma
    Davis, LM
  • Gene expression profiling predicts clinical outcome of breast cancer
    van 't Veer, LJ
  • Improvement of the clinical applicability of the genomic grade index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
    Toussaint, J
  • A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer
    Ma, XJ
  • Novel prognostic immunohistochemical biomarker panel for estrogen receptor–positive breast cancer
    Ring, BZ